Spago Nanomedical AB (SPAGO) - Total Assets
Based on the latest financial reports, Spago Nanomedical AB (SPAGO) holds total assets worth Skr36.68 Million SEK (≈ $3.95 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Spago Nanomedical AB - Total Assets Trend (2011–2025)
This chart illustrates how Spago Nanomedical AB's total assets have evolved over time, based on quarterly financial data. Also see SPAGO market cap for the company's overall valuation and market capitalisation.
Spago Nanomedical AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Spago Nanomedical AB's total assets of Skr36.68 Million consist of 98.0% current assets and 2.0% non-current assets. Review total liabilities of Spago Nanomedical AB to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 80.9% |
| Accounts Receivable | Skr117.00K | 0.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Spago Nanomedical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SPAGO stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Spago Nanomedical AB's current assets represent 98.0% of total assets in 2025, an increase from 6.3% in 2011.
- Cash Position: Cash and equivalents constituted 80.9% of total assets in 2025, up from 5.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 90.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Spago Nanomedical AB Competitors by Total Assets
Key competitors of Spago Nanomedical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Spago Nanomedical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.96 | 6.58 | 25.34 |
| Quick Ratio | 6.96 | 6.58 | 25.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr30.77 Million | Skr32.72 Million | Skr84.00 Million |
Spago Nanomedical AB - Advanced Valuation Insights
This section examines the relationship between Spago Nanomedical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.77 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | Skr36.68 Million |
| Market Capitalization | $6.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Spago Nanomedical AB's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Spago Nanomedical AB's assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Spago Nanomedical AB (2011–2025)
The table below shows the annual total assets of Spago Nanomedical AB from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr36.68 Million ≈ $3.95 Million |
-7.33% |
| 2024-12-31 | Skr39.58 Million ≈ $4.26 Million |
-25.29% |
| 2023-12-31 | Skr52.98 Million ≈ $5.70 Million |
-74.27% |
| 2022-12-31 | Skr205.95 Million ≈ $22.16 Million |
+7.48% |
| 2021-12-31 | Skr191.62 Million ≈ $20.62 Million |
+17.69% |
| 2020-12-31 | Skr162.82 Million ≈ $17.52 Million |
+15.85% |
| 2019-12-31 | Skr140.54 Million ≈ $15.12 Million |
+11.26% |
| 2018-12-31 | Skr126.32 Million ≈ $13.59 Million |
+13.20% |
| 2017-12-31 | Skr111.59 Million ≈ $12.01 Million |
+39.38% |
| 2016-12-31 | Skr80.06 Million ≈ $8.62 Million |
+7.13% |
| 2015-12-31 | Skr74.73 Million ≈ $8.04 Million |
-1.12% |
| 2014-12-31 | Skr75.58 Million ≈ $8.13 Million |
+30.61% |
| 2013-12-31 | Skr57.87 Million ≈ $6.23 Million |
+7.94% |
| 2012-12-31 | Skr53.61 Million ≈ $5.77 Million |
+112.18% |
| 2011-12-31 | Skr25.27 Million ≈ $2.72 Million |
-- |
About Spago Nanomedical AB
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more